Surgical Outcomes in Gastric Cancer

Publication
Article
OncologyONCOLOGY Vol 11 No 12
Volume 11
Issue 12

The enormous influence of the surgeon on outlook in cancer was stressed by Professor Cornelis van de Velde of the Department of Surgery, Leiden University Medical Center, the Netherlands, during the 1997 European Cancer Conference.

The enormous influence of the surgeon on outlook in cancer was stressed by Professor Cornelis van de Velde of the Department of Surgery, Leiden University Medical Center, the Netherlands, during the 1997 European Cancer Conference.

“Quality of surgery can make the most tremendous difference to your chances of survival and the quality of a patient’s remaining life,” said Professor van de Velde. “In rectal cancer, for example, the local recurrence rate can vary enormously between surgeons, from 5% to 50% or 60%, and this can affect not only your risk of dying of metastases, but the degree of suffering. Many local recurrences in rectal cancer are untreatable and cause immense and unbearable symptoms.”

“Survival rates in gastric and rectal cancer can vary as much as 5% to 10% between different surgeons, more than the effect gained from adjuvant treatment.” Professor van de Velde continued. “Morbidity, mortality and survival vary substantially between surgeons. Also more extensive surgery does not necessarily improve survival, so addressing the issues about individual surgical performance is a major issue.” 

Recent Videos
Providing easier access to ancillary services for patients with PDAC who live farther away from the treatment center may help them complete the treatment regimen.
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Prolonging systemic therapy in patients with gastric or gastroesophageal junction cancers may offer better outcomes than radiation therapy.
Advances in perioperative targeted therapies may enable organ preservation and significantly enhance outcomes for patients with gastric cancers.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Related Content